[CAS NO. 59703-84-3] Piperacillin sodium

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [59703-84-3]

Catalog

HY-B1286

Brand

MCE

CAS

59703-84-3

DESCRIPTION [59703-84-3]

Overview

MDL	MFCD00917471
Molecular Weight	539.54
Molecular Formula	C23H26N5NaO7S
SMILES	O=C([C@@H](C(C)(C)S[C@]1([H])[C@@H]2NC([C@H](NC(N3C(C(N(CC)CC3)=O)=O)=O)C4=CC=CC=C4)=O)N1C2=O)O[Na]

For research use only. We do not sell to patients.

3 Publications Citing Use of MCE

Summary

Piperacillin sodium is a broad-spectrum β-lactam antibiotic .

IC50 & Target

β-lactam

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT05608564	University of Belgrade	Periodontitis	January 17, 2022	Not Applicable
NCT02817347	Yuhan Corporation	Otitis Media\|Otorrhea	June 2016	Phase 1\|Phase 2
NCT05355350	Rambam Health Care Campus\|The Chaim Sheba Medical Center\|Rabin Medical Center\|Hadassah Medical Organization	Beta Lactam Resistant Bacterial Infection\|Enterobacteriaceae Infections\|Bacteremia	July 1, 2022	Phase 4
NCT01760109	Xiangbei Welman Pharmaceutical Co., Ltd	Respiratory Tract Infections\|Urinary Tract Infections	July 2011	Phase 4
NCT03765645	Institute of Liver and Biliary Sciences, India	Antibiotic Prophylaxis\|Postoperative Infection	October 4, 2018	Not Applicable
NCT04530045	Central Hospital, Nancy, France	Critical Illness\|Antibiotic Toxicity\|Sepsis\|Septic Shock	May 2, 2018
NCT01714557	Chinese PLA General Hospital	Neutropenia\|Hematopoietic Stem Cell Transplantation	September 2012	Not Applicable
NCT03932123	Shandong University\|Tianjin Central Hospital of Gynecology Obstetrics\|Shandong Provincial Hospital\|Qianfoshan Hospital	Early Onset Neonatal Sepsis	May 5, 2019
NCT02493764	Merck Sharp & Dohme LLC	Bacterial Pneumonia	November 24, 2015	Phase 3
NCT03990467	Hospices Civils de Lyon	Septic Shock\|Sepsis\|Sepsis Syndrome	January 28, 2021	Not Applicable
NCT05060419	Qilu Pharmaceutical Co., Ltd.	Complicated Urinary Tract Infection\|Acute Pyelonephritis	October 8, 2021	Phase 2
NCT03628300	Centre Hospitalier Universitaire, Amiens	Neurotoxicity\|Sepsis	January 1, 2017
NCT02473263	Assistance Publique - Hôpitaux de Paris	Severe Septic Syndrome (Severe Sepsis and Septic Shock) Diagnosed and Treated by Mobile Intensive Care Unit	May 9, 2016	Phase 3
NCT04948463	Murdoch Childrens Research Institute	Febrile Neutropenia	November 15, 2021	Phase 4
NCT01697059	Rhode Island Hospital	Acute Appendicitis	September 2012	Not Applicable
NCT00389987	Merck Sharp & Dohme LLC	Complicated Intra-Abdominal Infections	September 2001	Phase 3
NCT01805856	Ito Hospital	Thyroid Disease\|Parathyroid Disease	November 2010	Not Applicable
NCT03685084	Allecra	Healthy	October 10, 2013	Phase 1
NCT01667094	The Alfred	Cystic Fibrosis	September 2012	Phase 4
NCT00003805	European Organisation for Research and Treatment of Cancer - EORTC	Bone Marrow Suppression\|Fever, Sweats, and Hot Flashes\|Infection\|Leukemia\|Lymphoma\|Multiple Myeloma and Plasma Cell Neoplasm\|Myelodysplastic Syndromes\|Unspecified Adult Solid Tumor, Protocol Specific\|Unspecified Childhood Solid Tumor, Protocol Specific	November 1997	Phase 3
NCT01198925	University Hospital, Ghent	Infectious Disease	September 23, 2010	Phase 4
NCT00894439	Wyeth is now a wholly owned subsidiary of Pfizer	Healthy Subjects	May 2009	Phase 1

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 185.34 mM ; Need ultrasonic)

H ₂ O : ≥ 100 mg/mL ( 185.34 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.8534 mL	9.2672 mL	18.5343 mL
5 mM	0.3707 mL	1.8534 mL	3.7069 mL
10 mM	0.1853 mL	0.9267 mL	1.8534 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 100 mg/mL (185.34 mM); Clear solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (4.63 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (4.63 mM); Clear solution
4.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (4.63 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(2R)-2-[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-, sodium salt (1:1), (2S,5R,6R)-

4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, monosodium salt, [2S-[2α,5α,6β(S*)]]-

4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(2R)-[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, monosodium salt, (2S,5R,6R)-

T 1220

Piperacillin sodium

Sodium piperacillin

Piperacillin-Na

Pentcillin

CL 227193